Orforglipron: Australia’s first non-peptide oral GLP-1

1 minute read


Endocrinologist Dr Ted Wu examines how Orforglipron broadens access to GLP-1 therapy with an oral formulation and practical guidance for use in clinical practice.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×